Bionano Strategy Day Highlighted the Company’s Strategic Initiatives and Growth Plans as well as OGM’s Competitive Value for Cell Bioprocessing, and Cancer and Genetic Disease Research
- Bionano’s chief executive officer, chief financial officer, chief medical officer, chief operating officer and vice president of clinical and scientific affairs delivered an in-depth review of the company’s strategy, growth drivers, and financial objectives, as well as key initiatives related to clinical trials and new product advancements
Dan Brennan , ManagingDirector, Research, Healthcare, Cowen & Co. moderated a series of panel discussions with key opinion leaders (KOLs) and management including:- A panel covering clinical research applications of optical genome mapping (OGM) with Drs.
Adam Smith ,University Health Network ,University of Toronto ,Gordana Raca , Children’s Hospital Los Angeles, andRavindra Kolhe ,Georgia Cancer Center ,Medical College of Georgia - A panel covering translational research applications of OGM with Drs.
Ben Finlay ,Sanford Burnham Prebys Medical Discovery Institute ,Catherine Brownstein , Boston Children’s Hospital, andRashmi Kanagal-Shamanna ,University of Texas MD Anderson Cancer Center - A fireside chat with
Erik Holmlin , Bionano’s president and chief executive officer and a Q&A panel with Bionano’s management team
- A panel covering clinical research applications of optical genome mapping (OGM) with Drs.
- On-demand webcast from Strategy Day and supporting materials are available on the company’s Investor Relations site
Bionano outlined the aim to transform cytogenetic analysis for cancer and genetic disease research through its digital workflow, which can provide increased resolution and success rates compared to traditional cytogenetic methods.
- Bionano is targeting three large segments of the genomics market: cell bioprocessing, cancer research and genetic disease research: Presentations covered the company’s plans to target for existing sample volumes in these key areas to be analyzed by optical genome mapping (OGM) as an alternative to traditional cytogenetic methods and as well a complement to next-generation sequencing (NGS).
- Bionano’s business strategy includes a focus on key catalysts that will drive product development, regulatory approval and reimbursement for OGM-based tests through coding and coverage: Leadership team members described strategies to promote increased OGM adoption in target markets through product improvements, including the anticipated launches of the Ionic® and high throughput Saphyr® systems, the expansion of sample prep menus, and improved analysis and reporting software. Presentations also addressed plans to seek regulatory approval for certain of the company’s products, as well as reimbursement for OGM-based laboratory developed tests.
- OGM can offer clinical and translational researchers genome analysis with high resolution and sensitivity, a simple and easy to implement workflow, and fast turnaround times: Researchers at the event described how OGM can provide laboratories with a simpler workflow, improved turnaround times and more cost-efficient processing of specimens in a more scalable approach than standard workflows. Panelists also noted OGM’s low operationalization risk, minimal training barriers, and quick positive impact on their lab.
An on-demand webcast of the event is available here with free registration. A copy of the Strategy Day presentation can be viewed on the Investor Relations page on the company’s website at https://ir.bionanogenomics.com/.
About
Bionano’s products are for research use only. Not for use in diagnostic procedures.
Forward-Looking Statements of
This press release contains forward-looking statements contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “plan," “anticipate,” “believe,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: (1) the impact and utility of optical genome mapping (OGM) in cancer and genetic disease research, and expected improvements to OGM over time; (2) the impact and utility of OGM for bioprocessing, including gene editing and genome integrity analysis; (3) the ability and utility of applying OGM data as a complement to sequencing data; (4) the ability and utility of OGM to be complementary to, or used in lieu of, traditional cytogenomics methods for analysis of structural variations; (5) anticipated goals and milestones for OGM and Bionano; (6) our ability to stay in front of competitors' improvements in technologies; (7) the anticipated benefits and ultimate success of our collaborations; (8) our growth prospects and future financial and operating performance and results; (9) our potential market opportunity and estimates of its size; (10) our future products and features; (11) our anticipated growth strategies and anticipated trends in our business; and (12) other statements that are not historical facts.
Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: (1) the impact of geopolitical and macroeconomic developments, such as the ongoing
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com

Source: Bionano Genomics